Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy
Article Abstract:
Enoxaparin has shown better results over unfractionated heparin in low-to-moderate risk patients with non-ST-segment elevation acute coronary syndromes (ACS) and tests were conducted to compare the outcomes of patients treated with either of the drugs. Enoxaparin was not found to be superior to unfractionated heparin, but it is safe and an effective alternative.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Safety and efficacy of enoxaparin vs. unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin
Article Abstract:
Tests were conducted to check the efficacy of the combination of enoxaparin and tirofiban in comparison with unfractionated heparin and tirofiban in patients with non-ST-elevation acute coronary syndromes (ACS). It was found that in patients receiving tirofiban and aspirin enoxaparin is a good alternative when compared to unfractionated heparin.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Fractionating heparins and their clinical trial data-something for everyone
Article Abstract:
Heparin is known to reduce ischemic occurrences beyond that of aspirin in acute coronary setting and unfractionated heparin is known to have several limitations and inability to inhibit clot-bound thrombin. Trials show that enoxaparin is a good alternative to unfractionated heparin in regular acute coronary syndrome (ACS) treatment.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial
- Abstracts: Excision margins in high-risk malignant melanoma. A pooled analysis of bone marrow micrometastasis in breast cancer
- Abstracts: Cardiovascular effects of 6 months of hormone replacement therapy versus placebo: differences associated with years since menopause
- Abstracts: IL-23: A master regulator in Crohn disease. Negative regulation of airway responsiveness that is dependent on gamma/delta T cells and independent of alpha/beta T cells
- Abstracts: Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. Efficacy and safety of Emtricitabine vs. Stavudine in combination therapy in antiretroviral-naive patients